Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • 私たちの技術
  • ニュース
Header Image Frame Header Image Frame

News

ニュース

News

日本の腎がん治験の第I相試験登録の完了

ニュース, ビジネス,

Read more

日本での腎がん画像診断第I相臨床試験で最初の投薬が完了

ニュース, ビジネス,

Read more
1 2 3 4
Telix Pharmaceuticals Logo
  • ニュース
  • 私たちの技術

© 2023 Telix Pharmaceuticals Japan K.K, KRP #4 Building, 93 Chudoji-Awata-machi, Shimogyu-ku, Kyoto-shi, Kyoto, Japan.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au